{"organizations": [], "uuid": "003fd7d6830d071caad34ed0f153af5dd3a06633", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aeterna-zentaris-enters-licensing/brief-aeterna-zentaris-enters-licensing-agreement-with-strongbridge-for-macrilen-in-u-s-canada-idUSFWN1PC0YF", "country": "US", "domain_rank": 408, "title": "BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.026, "site_type": "news", "published": "2018-01-17T20:47:00.000+02:00", "replies_count": 0, "uuid": "003fd7d6830d071caad34ed0f153af5dd3a06633"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aeterna-zentaris-enters-licensing/brief-aeterna-zentaris-enters-licensing-agreement-with-strongbridge-for-macrilen-in-u-s-canada-idUSFWN1PC0YF", "ord_in_thread": 0, "title": "BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada", "locations": [], "entities": {"persons": [], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aeterna zentaris inc", "sentiment": "negative"}, {"name": "zentaris", "sentiment": "negative"}, {"name": "zentaris inc", "sentiment": "none"}, {"name": "macrilen", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Aeterna Zentaris Inc:\n* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA\n* AETERNA ZENTARIS INC - ‍THROUGH SUBSIDIARY, ENTERED LICENSE AND ASSIGNMENT AGREEMENT WITH SUBSIDIARY OF STRONGBRIDGE BIOPHARMA ​\n* AETERNA ZENTARIS INC - ‍ FOR AS LONG AS MACRILEN IS PATENT-PROTECTED, CO TO BE ENTITLED TO A 15 PERCENT ROYALTY ON NET SALES UP TO US$75 MILLION\n* AETERNA ZENTARIS INC - ‍ FOR AS LONG AS MACRILEN IS PATENT-PROTECTED, CO TO BE ENTITLED TO A 18 PERCENT ROYALTY ON NET SALES OVER US$75 MILLION\n* AETERNA ZENTARIS - ‍COMMITTEE WITH OVERSIGHT OF PEDIATRIC DEVELOPMENT PGM TO BE MADE OF 4 PERSONS,2 OF WHOM TO BE APPOINTED BY EACH OF STRONGBRIDGE, CO Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T20:47:00.000+02:00", "crawled": "2018-01-18T16:09:00.004+02:00", "highlightTitle": ""}